# US 2016/0251648 A1 · Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251648 A1
- Document ID: US20160251648A1
- Status: Published application
- Kind: A1
- Application number: 15/141,348
- Filed: 2016-04-28
- Published: 2016-09-01
- Earliest claimed: 2013-10-28
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research
- Applicants: The Broad Institute Inc.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research
- Inventors: Tim Wang; David Sabatini; Eric Lander
- Web page: https://patentgrep.com/patent/US20160251648A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/907: {in mammalian cells}
- C12N 2310/10: Type of nucleic acid
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2330/31: Libraries, arrays
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention generally relates to libraries, kits, methods, applications and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. The present invention also relates to rules for making potent single guide RNAs (sgRNAs) for use in CRISPR-Cas systems. Provided are genomic libraries and genome wide libraries, kits, methods of knocking out in parallel every gene in the genome, methods of selecting individual cell knock outs that survive under a selective pressure, methods of identifying the genetic basis of one or more medical symptoms exhibited by a patient, and methods for designing a genome-scale sgRNA library.

## Claims

### Claim 1

A genomic library comprising a selected plurality of unique CRISPR-Cas system guide sequences that are capable of targeting a plurality of target sequences in genomic loci of a plurality of genes, wherein said targeting results in a knockout of gene function, wherein the unique CRISPR-Cas system guide sequences are selected by an algorithm that predicts the efficacy of the guide sequences based on the primary nucleotide sequence of the guide sequence and/or by a heuristic that ranks the guide sequences based on off target scores.

### Claim 2 (depends on 1)

The genomic library of claim 1, wherein the guide sequences have a % GC nucleotide content between 20-80%.

### Claim 3 (depends on 2)

The genomic library of claim 2, wherein the % GC nucleotide content is between 30-70%.

### Claim 4 (depends on 1, 2, 3)

The genomic library of any of claims 1 to 3, wherein the guide sequences target constitutive exons downstream of a start codon of the gene.

### Claim 5 (depends on 1, 2, 3, 4)

The genomic library of any of claims 1 to 4, wherein the guide sequences target either a first or a second exon of the gene.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The genomic library of any of claims 1 to 5, wherein the guide sequences target a non-transcribed strand of the genomic loci of the gene.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The genomic library of any of claims 1 to 6, wherein the guide sequence is 20 nucleotides long and likelihood of nucleotide T being at nucleotide position 17, 18, 19 or 20 is less than 20%.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The genomic library of any of claims 1 to 7, wherein the guide sequences with the lowest off target scores are highly ranked and are selected.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The genomic library of any of claims 1 to 8, wherein the guide sequences do not have off target scores greater than 400.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The genomic library of any of claims 1 to 9, wherein a plurality of target sequences in each gene are targeted.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method of knocking out in parallel every gene in the genome, the method comprising contacting a population of cells with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transduced with a single packaged vector,
selecting for successfully transduced cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claims 1-9,
wherein the guide sequence targets the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product and whereby each cell in the population of cells has a unique gene knocked out in parallel.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of selecting individual cell knock outs that survive under a selective pressure, the method comprising
contacting a population of cells with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transduced with a single packaged vector,
selecting for successfully transduced cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claims 1-10,
wherein the guide sequence targets the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product, whereby each cell in the population of cells has a unique gene knocked out in parallel,
applying the selective pressure,
and selecting the cells that survive under the selective pressure.

### Claim 13 (depends on 12)

The method of claim 12, wherein the method further comprises extracting DNA and determining the depletion or enrichment of the guide sequences by deep sequencing.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method of identifying the genetic basis of one or more medical symptoms exhibited by a subject, the method comprising
obtaining a biological sample from the subject and isolating a population of cells having a first phenotype from the biological sample;
contacting the cells having the first phenotype with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transduced with a single packaged vector,
selecting for successfully transduced cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claims 1-9,
wherein the guide sequence targets the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product, whereby each cell in the population of cells has a unique gene knocked out in parallel,
applying a selective pressure,
selecting the cells that survive under the selective pressure,
determining the genomic loci of the DNA molecule that interacts with the first phenotype and identifying the genetic basis of the one or more medical symptoms exhibited by the subject.

### Claim 15 (depends on 11, 12)

The method of claim 11, 12, or 14, wherein the selective pressure is application of a drug, FACS sorting of cell markers or aging.

### Claim 16 (depends on 11, 12, 14)

The method of claim 11, 12, 14, or 15, wherein the cell is a eukaryotic cell.

### Claim 17 (depends on 11, 12)

The method of claims 11, 12, or 14 to 16, wherein the eukaryotic cell is a human cell.

### Claim 18 (depends on 11, 12)

The method of claims 11, 12, or 14 to 17, wherein the vector is a lentivirus, an adenovirus or an AAV.

### Claim 19 (depends on 11, 12)

The method of claims 11, 12, or 14 to 18, wherein the first regulatory element is a U6 promoter.

### Claim 20 (depends on 11, 12)

The method of claims 11, 12, or 14 to 19, wherein the second regulatory element is an EFS promoter or a doxycycline inducible promoter.

### Claim 21 (depends on 11, 12)

The method of claims 11, 12, or 14 to 20, wherein the vector system comprises one vector.

### Claim 22 (depends on 11, 12)

The method of claims 11, 12, or 14 to 21, wherein the CRISPR enzyme is Cas9.

### Claim 23 (depends on 11, 12)

The method of claims 11, 12, or 14 to 22, wherein the cell is transduced with a multiplicity of infection (MOI) of 0.3-0.75.

### Claim 24 (depends on 23)

The method of claim 23, wherein the MOI is 0.3 or 0.4.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A kit comprising the library of claims 1-10.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25)

The kit of claim 25, wherein the kit comprises a single container comprising vectors comprising the library of claims 1-10.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 26)

The kit of claim 25 or 26, wherein the kit comprises a single container comprising plasmids comprising the library of claims 1-10.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A kit comprising a panel comprising a selection of unique CRISPR-Cas system guide sequences from the library of claims 1-10, wherein the selection is indicative of a particular physiological condition.

### Claim 29

The library or method of any one of the preceding claims, wherein the targeting is of about 100 or more sequences, about 1000 or more sequences or about 20,000 or more sequences or the entire genome.

### Claim 30

The library or method of any one of the preceding claims, wherein a panel of target sequences is focused on a relevant or desirable pathway, such as an immune pathway or a cell division pathway.

### Claim 31

Non-transitory computer program product comprising one or more stored sequences of instructions that is accessible to a processor and which, when executed by the processor, causes the processor to carry out a machine learning algorithm (support vector machine—SVM) that predicts the efficacy of a sgRNA based solely on the primary sequence of the sgRNA.

### Claim 32

A genome wide library comprising a plurality of unique CRISPR-Cas system guide sequences that are capable of targeting a plurality of target sequences in genomic loci, wherein said targeting results in a knockout of gene function.

### Claim 33 (depends on 32)

A method of knocking out in parallel every gene in the genome, the method comprising
contacting a population of cells with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transfected with a single packaged vector,
selecting for successfully transfected cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claim 32,
wherein the guide RNAs target the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product and whereby each cell in the population of cells has a unique gene knocked out in parallel.

### Claim 34 (depends on 33)

The method of claim 33 wherein the cell is a eukaryotic cell.

### Claim 35 (depends on 33)

The method of claim 33 wherein the vector is a lentivirus, a adenovirus or a AAV.

### Claim 36 (depends on 33)

The method of claim 33 wherein the first regulatory element is a U6 promoter.

### Claim 37 (depends on 33)

The method of claim 33 wherein the second regulatory element is an EFS promoter.

### Claim 38 (depends on 33)

The method of claim 33 wherein the vector system comprises one vector.

### Claim 39 (depends on 33)

The method of claim 33 wherein the CRISPR enzyme is Cas9.

### Claim 40 (depends on 32)

A method of selecting individual cell knock outs that survive under a selective pressure, the method comprising
contacting a population of cells with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transfected with a single packaged vector,
selecting for successfully transfected cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claim 32,
wherein the guide RNAs target the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product, whereby each cell in the population of cells has a unique gene knocked out in parallel,
applying the selective pressure,
and selecting the cells that survive under the selective pressure.

### Claim 41 (depends on 40)

The method of claim 40 wherein the selective pressure is application of a drug, FACS sorting of cell markers or aging.

### Claim 42 (depends on 40)

The method of claim 40 wherein the cell is a eukaryotic cell.

### Claim 43 (depends on 40)

The method of claim 40 wherein the vector is a lentivirus, a adenovirus or a AAV.

### Claim 44 (depends on 40)

The method of claim 40 wherein the first regulatory element is a U6 promoter.

### Claim 45 (depends on 40)

The method of claim 40 wherein the second regulatory element is an EFS promoter.

### Claim 46 (depends on 40)

The method of claim 40 wherein the vector system comprises one vector.

### Claim 47 (depends on 40)

The method of claim 40 wherein the CRISPR enzyme is Cas9.

### Claim 48 (depends on 32)

A method of identifying the genetic basis of one or more medical symptoms exhibited by a subject, the method comprising
obtaining a biological sample from the subject and isolating a population of cells having a first phenotype from the biological sample;
contacting the cells having the first phenotype with a composition comprising a vector system comprising one or more packaged vectors comprising
a) a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence that targets a DNA molecule encoding a gene product,
wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
b) a second regulatory element operably linked to a Cas protein and a selection marker,
wherein components (a) and (b) are located on same or different vectors of the system,
wherein each cell is transfected with a single packaged vector,
selecting for successfully transfected cells,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in the genomic loci of the DNA molecule encoding the gene product,
wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the guide sequence is selected from the library of claim 32,
wherein the guide RNAs target the genomic loci of the DNA molecule encoding the gene product and the CRISPR enzyme cleaves the genomic loci of the DNA molecule encoding the gene product, whereby each cell in the population of cells has a unique gene knocked out in parallel,
applying the selective pressure,
selecting the cells that survive under the selective pressure,
determining the genomic loci of the DNA molecule that interacts with the first phenotype and identifying the genetic basis of the one or more medical symptoms exhibited by the subject.

### Claim 49 (depends on 48)

The method of claim 48 wherein the selective pressure is application of a drug, FACS sorting of cell markers or aging.

### Claim 50 (depends on 48)

The method of claim 48 wherein the cell is a eukaryotic cell.

### Claim 51 (depends on 48)

The method of claim 48 wherein the vector is a lentivirus, a adenovirus or a AAV.

### Claim 52 (depends on 48)

The method of claim 48 wherein the first regulatory element is a U6 promoter.

### Claim 53 (depends on 48)

The method of claim 48 wherein the second regulatory element is an EFS promoter.

### Claim 54 (depends on 48)

The method of claim 48 wherein the vector system comprises one vector.

### Claim 55 (depends on 48)

The method of claim 48 wherein the CRISPR enzyme is Cas9.

### Claim 56 (depends on 32)

A kit comprising the library of claim 32.

### Claim 57 (depends on 32, 56)

The kit of claim 56, wherein the kit comprises a single container comprising vectors comprising the library of claim 32.

### Claim 58 (depends on 32, 56)

The kit of claim 56, wherein the kit comprises a single container comprising plasmids comprising the library of claim 32.

### Claim 59 (depends on 32)

A kit comprising a panel comprising a selection of unique CRISPR-Cas system guide sequences from the library of claim 32, wherein the selection is indicative of a particular physiological condition.

### Claim 60 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The library or method of any one of claims 32 to 59, wherein the targeting is of about 100 or more sequences, about 1000 or more sequences or about 20,000 or more sequences or the entire genome.

### Claim 61 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The library or method of any one of claims 32 to 60, wherein a panel of target sequences is focused on a relevant or desirable pathway, such as an immune pathway or cell division.

### Claim 62

Method for designing a genome-scale sgRNA library, the method comprising
identifying early constitutive exons for all coding genes,
selecting sgRNAs to target these early constitutive exons by choosing sgRNAs that were predicted to have minimal off-target activity,
for each candidate exon, listing all possible S. pyogenes Cas9 sgRNA sequences of the form (N)20NGG as candidate targets,
mapping each 20 mer candidate sgRNA to a precompiled index containing all 20 mer sequences in the human genome followed by either NGG or NAG,
ranking sgRNAs for each exon based on the characterized sequence specificity of Cas9 nuclease by using the following heuristic:
discarding sgRNAs with other targets in the genome that match exactly or differ by only 1 base
calculating for the remaining sgRNAs the following off target score:
OS
=
∑
off


targets

(
sum


m


m


location
)

(
D

(
m


m
)

/

D

(
max
)
)
sum mm location=sum of the mismatch locations from 3′ to 5′. The PAM (NGG) proximal base is 1 and the PAM distal base is 20.
D(mm)=distance in by between mismatch locations.
D(max)=maximal possible distance between 2 or 3 mismatches.
